Monday - July 14, 2025

LOGIN  |  REGISTER
Terns Pharmaceuticals
Cue Biopharma

Agilent Technologies to Announce Second-Quarter Fiscal Year 2024 Financial Results May 29

May 02, 2024 | Last Trade: US$123.28 0.89 -0.72

SANTA CLARA, Calif. / May 02, 2024 / Business Wire / Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2024 after the stock market closes on May 29. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PT.

To join the listen-only conference call webcast, click the link on the Events section of Agilent’s investor relations website. A recording of the call will also be available on the website for 90 days.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Recursion

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page